These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 7780695)

  • 1. [The usefulness of morphologic methods for prognosis and treatment of breast carcinoma].
    Niezabitowski A
    Pol J Pathol; 1995; 46(1):3-10. PubMed ID: 7780695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prognostic-predictive factors and therapeutic choices in invasive carcinoma of the breast].
    Puglisi F; Di Loreto C; Beltrami CA
    Ann Ital Chir; 1999; 70(3):335-41. PubMed ID: 10466235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prognostic factors and therapeutic strategy of breast cancer].
    Namer M; Ramaioli A; Hery M; Ferrero JM
    Rev Prat; 1998 Jan; 48(1):45-51. PubMed ID: 9781209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor.
    Chang J; Clark GM; Allred DC; Mohsin S; Chamness G; Elledge RM
    Cancer; 2003 Feb; 97(3):545-53. PubMed ID: 12548595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Future prospects for the staging of breast cancer.
    Rutgers EJ; Peterse HL
    Semin Surg Oncol; 1996; 12(1):3-11. PubMed ID: 8821404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast biopsies: the content of the surgical pathology report.
    Kamel OW; Hendrickson MR; Kempson RL
    Pathology (Phila); 1992; 1(1):161-80. PubMed ID: 9420919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical characteristics and prognosis of breast cancer patients with vascular invasion].
    Zhao WH; Xu BH; Zhang P; Li Q; Zhao LM; Sun Y
    Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):137-40. PubMed ID: 17645853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
    Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
    Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 mutations in breast cancer: incidence and relations to tumor aggressiveness and evolution of the disease.
    Bautista S; Theillet C
    Pathol Biol (Paris); 1997 Dec; 45(10):882-92. PubMed ID: 9769953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical evaluation of a panel of mRNA markers in the detection of disseminated tumor cells in patients with operable breast cancer.
    Varangot M; Barrios E; Sóñora C; Aizen B; Pressa C; Estrugo R; Lavigna R; Musé I; Osinaga E; Berois N
    Oncol Rep; 2005 Aug; 14(2):537-45. PubMed ID: 16012742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of pathology in premalignancy and as a guide for treatment and prognosis in breast cancer.
    Simpson JF; Page DL
    Semin Oncol; 1996 Aug; 23(4):428-35. PubMed ID: 8757269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined flow cytometry determination of S-phase fraction and DNA ploidy is an independent prognostic factor in node-negative invasive breast carcinoma: analysis of a series of 271 patients with stage I and II breast cancer.
    Moureau-Zabotto L; Bouchet C; Cesari D; Uzan S; Lefranc JP; Antoine M; Genestie C; Deniaud-Alexandre E; Bernaudin JF; Touboul E; Fleury-Feith J
    Breast Cancer Res Treat; 2005 May; 91(1):61-71. PubMed ID: 15868432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical relevance of the distribution of the lesions in 500 consecutive breast cancer cases documented in large-format histologic sections.
    Tot T
    Cancer; 2007 Dec; 110(11):2551-60. PubMed ID: 17932896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast cancer heterogeneity assessed by flow cytometry.
    Savarese A; Vecchione A
    In Vivo; 1993; 7(6B):631-4. PubMed ID: 8193285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Combined flow cytometry determination of S-phase fraction and DNA ploidy is an independent prognostic factor in node-negative invasive breast carcinoma: review of a series of 271 patients with stage I and II breast cancer].
    Moureau-Zabotto L; Bouchet C; Cesari D; Uzan S; Lefranc JP; Antoine M; Genestie C; Deniaud-Alexandre E; Bernaudin JF; Touboul E; Fleury-Feith J
    Cancer Radiother; 2005 Dec; 9(8):575-86. PubMed ID: 16243560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors for patients with liver metastases from breast cancer.
    Eichbaum MH; Kaltwasser M; Bruckner T; de Rossi TM; Schneeweiss A; Sohn C
    Breast Cancer Res Treat; 2006 Mar; 96(1):53-62. PubMed ID: 16319993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical and morphologic features and methods of treatment of non-invasive breast cancer].
    Semiglazov VV; Semiglazov VF
    Vopr Onkol; 2001; 47(3):278-89. PubMed ID: 11544824
    [No Abstract]   [Full Text] [Related]  

  • 18. Implications of the new biology for therapy in breast cancer.
    Sledge GW
    Semin Oncol; 1996 Feb; 23(1 Suppl 2):76-81. PubMed ID: 8614850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA flow cytometric measurements in breast cancer: a review of the instrumentation principles and clinical significance.
    Berho M; Viciana AL; Poppiti RJ; Ruiz P
    J Fla Med Assoc; 1997 Feb; 84(2):104-10. PubMed ID: 9066236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In lymph node-negative invasive breast carcinomas, specific chromosomal aberrations are strongly associated with high mitotic activity and predict outcome more accurately than grade, tumour diameter, and oestrogen receptor.
    Janssen EA; Baak JP; Guervós MA; van Diest PJ; Jiwa M; Hermsen MA
    J Pathol; 2003 Dec; 201(4):555-61. PubMed ID: 14648658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.